OAK BROOK, Ill.--(BUSINESS WIRE)--Feb. 1, 2006--Bio-Bridge Science Inc. (OTCBB:BGES), a development-stage biotech company, reported encouraging results for pharmacological and acute toxicity studies on its HIV therapeutic Vaccine (HIV-PV pseudovirus) on mice and monkeys. The vaccine, based on exclusive technology co-developed by CEO Liang Qiao, an associate professor at Loyola University Chicago’s Stritch School of Medicine, targets infection in mucosal tissues, the first type of tissue attacked by HIV.
